From the ONCX filings in early 2017. "Our initial commercial focus is the development of Prolanta™ for the treatment of ovarian cancer. We have commenced a Phase 1 clinical trial after receiving clearance from the FDA.We completed the first dosing group of 3 subjects in the Phase I clinical trial, with no evidence of serious adverse events or dose-limiting toxicities."
Has anyone noticed that ONCX is nearling the completion date of the second dosing group?
Are both the FDA and SEC assisting ONCX in fraud?
Of course not.
These are facts. Not up for debate by any rational person.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.